immune-profiling
(3)
BostonGene
BostonGene is a Waltham, Massachusetts biotechnology company that applies AI-driven multiomics to cancer. Its Tumor Portrait platform integrates DNA and RNA sequencing with immune and tumor-microenvironment analysis into a single test, producing molecular profiles that help oncologists select therapies and help pharmaceutical partners design trials, identify biomarkers, and accelerate drug development. Founded in 2015 and led by CEO Andrew Feinberg, the company reached unicorn status in 2022.
Inflammatix, Inc.
Inflammatix is a Sunnyvale, California molecular diagnostics company that reads the body's own immune response instead of hunting for the pathogen. Its FDA-cleared TriVerity test measures 29 host mRNAs from a blood sample and, using machine-learning algorithms, returns three scores in about 30 minutes: likelihood of bacterial infection, likelihood of viral infection, and overall illness severity. Run on the company's benchtop Myrna instrument, it is built for emergency and critical-care clinicians who need to decide fast whether a patient is heading toward sepsis. Spun out of Stanford in 2016, the company has raised more than $205M.
Tim Sweeney
Tim Sweeney is the co-founder and CEO of Inflammatix, a Sunnyvale molecular diagnostics company that reads the immune system instead of hunting for pathogens. A surgeon-turned-entrepreneur with an MD/PhD from Duke and a biomedical informatics background from Stanford, he built TriVerity, an FDA-cleared rapid blood test that measures 29 immune-response genes and uses machine learning to score the likelihood of bacterial infection, viral infection, and severe illness. He has raised more than $200 million to bring precision medicine to sepsis and critical care.